The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study
Open accessAbstract
Etomoxir is an inhibitor of mitochondrial CPT1 (carnitine palmitoyltransferase 1) and thereby switches energy metabolism from fatty acids to glucose oxidation. Such a metabolic change may be beneficial in CHF (congestive heart failure). The ERGO (etomoxir for the recovery of glucose oxidation) study was designed in which etomoxir was tested at a dose of 80 and 40 mg compared with placebo for a period of 6 months in patients with CHF. As the principle measure of efficacy, a maximal exercise tolerance test and a submaximal 6-min corridor walk test were used. Secondary end points were echocardiographical dimensions and quality-of-life assessment scores. A total of 350 patients were planned to be screened, with the expectation that end point data would be available from approx. 260 patients. However, the study had to be stopped prematurely, because unacceptably high liver transaminase levels were detected in four patients taking etomoxir. At the termination of the study, 121 patients were randomized to placebo, 118 to 40 mg of etomoxir and 108 to 80 mg of etomoxir. At that time, 21 patients in the placebo group, 16 in the 40 mg of etomoxir group and 14 patients in the 80 mg of etomoxir group had completed the study. The mean increases in exercise time were 3.3, 10.2 and 19.4 s for the placebo, 40 mg of etomoxir and 80 mg of etomoxir groups respectively (P value was not significant). No changes were obvious in the 6-min corridor walk test or in echocardiographical parameters from baseline. The number of patients that completed the study was too small to demonstrate significant effects on exercise time, although there was a tendency towards an increase in exercise time. Therefore, before rejecting the hypothesis that inhibition of fatty acid oxidation might be beneficial in CHF, similar studies have to be performed using different inhibitors of fatty acid oxidation targeting CPT1 and other enzymes in this metabolic pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Cited by
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Cardiac Energy Metabolism in Heart Failure
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021) · Circulation Research · doi:10.1161/circresaha.121.318241 · Cited by 1,373
Cancer metabolism: fatty acid oxidation in the limelight
Carracedo, A., Cantley, L. C., & Pandolfi, P. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3483 · Cited by 1,324
Metabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877
Lipid metabolism in cancer: New perspectives and emerging mechanisms
Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V., & Fendt, S.-M. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.04.013 · Cited by 758
CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential
Schlaepfer, I. R., & Joshi, M. (2020) · Endocrinology · doi:10.1210/endocr/bqz046 · Cited by 732
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
Camarda, R., Zhou, A. Y., Kohnz, R. A., Balakrishnan, S., Mahieu, C., Anderton, B., Eyob, H., Kajimura, S., Tward, A., Krings, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4055 · Cited by 528
Metabolic Mechanisms in Heart Failure
Ashrafian, H., Frenneaux, M. P., & Opie, L. H. (2007) · Circulation · doi:10.1161/circulationaha.107.702795 · Cited by 521
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Jin, H.-R., Wang, J., Wang, Z.-J., Xi, M.-J., Xia, B.-H., Deng, K., & Yang, J.-L. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01498-2 · Cited by 481
Murphy, E., Ardehali, H., Balaban, R. S., DiLisa, F., Dorn, G. W., Kitsis, R. N., Otsu, K., Ping, P., Rizzuto, R., Sack, M. N., et al. (2016) · Circulation Research · doi:10.1161/res.0000000000000104 · Cited by 458
Loss of Metabolic Flexibility in the Failing Heart
Karwi, Q. G., Uddin, G. M., Ho, K. L., & Lopaschuk, G. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00068 · Cited by 442
Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies
Soares, R. O. S., Losada, D. M., Jordani, M. C., Évora, P., & Castro-e-Silva, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205034 · Cited by 408
Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.015 · Cited by 400
CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis
Wang, Y.-N., Zeng, Z.-L., Lu, J., Wang, Y., Liu, Z.-X., He, M.-M., Zhao, Q., Wang, Z.-X., Li, T., Lu, Y.-X., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0384-z · Cited by 380
Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355
Regulatory enzymes of mitochondrial β‐oxidation as targets for treatment of the metabolic syndrome
Schreurs, M., Kuipers, F., & Van Der Leij, F. R. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00642.x · Cited by 296
Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 294
Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association
Taegtmeyer, H., Young, M. E., Lopaschuk, G. D., Abel, E. D., Brunengraber, H., Darley-Usmar, V., Des Rosiers, C., Gerszten, R., Glatz, J. F., Griffin, J. L., et al. (2016) · Circulation Research · doi:10.1161/res.0000000000000097 · Cited by 286
Tan, Z., Xiao, L., Tang, M., Bai, F., Li, J., Li, L., Shi, F., Li, N., Li, Y., Du, Q., et al. (2018) · Theranostics · doi:10.7150/thno.21451 · Cited by 271
Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells
Lin, H., Patel, S., Affleck, V. S., Wilson, I., Turnbull, D. M., Joshi, A. R., Maxwell, R., & Stoll, E. A. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now128 · Cited by 260
Ritterhoff, J., & Tian, R. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00887-x · Cited by 254
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
German, N. J., Yoon, H., Yusuf, R. Z., Murphy, J. P., Finley, L. W. S., Laurent, G., Haas, W., Satterstrom, F. K., Guarnerio, J., Zaganjor, E., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.014 · Cited by 156
Mitochondrial CPT1A: Insights into structure, function, and basis for drug development
Liang, K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1160440 · Cited by 156
“However, preclinical research was stopped because of hepatotoxicity after a phase II clinical trial (Holubarsch et al., 2007).”
BackgroundFuel availability and fate in cardiac metabolism: a tale of two substrates
Pascual, F., & Coleman, R. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.03.014 · Cited by 125
Shoda, L. K. M., Woodhead, J. L., Siler, S. Q., Watkins, P. B., & Howell, B. A. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1878 · Cited by 75
Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective
Missiaen, R., Morales-Rodriguez, F., Eelen, G., & Carmeliet, P. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.01.001 · Cited by 58
Joshi, M., Kim, J., D’Alessandro, A., Monk, E., Bruce, K., Elajaili, H., Nozik-Grayck, E., Goodspeed, A., Costello, J. C., & Schlaepfer, I. R. (2020) · Cancers · doi:10.3390/cancers12113431 · Cited by 54
Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06181-5 · Cited by 36
Ressa, A., Bosdriesz, E., de Ligt, J., Mainardi, S., Maddalo, G., Prahallad, A., Jager, M., de la Fonteijne, L., Fitzpatrick, M., Groten, S., et al. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000486 · Cited by 17
Rupp, T. P., Rupp, K. G., Alter, P., & Rupp, H. (2013) · Cardiology · doi:10.1159/000350656 · Cited by 12
Metadata
- Authors
- Holubarsch, C. J. F., Rohrbach, M., Karrasch, M., Boehm, E., Polonski, L., Ponikowski, P., & Rhein, S.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2007-07-13
- Volume
- 113
- Issue
- 4
- Pages
- 205-212
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2012740748
- Cited by
- 287
- References
- 45
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.